Detection of ALK fusion transcripts in plasma of non-small cell lung cancer patients using a novel RT-PCR based assay.

BACKGROUND

Detection of genomic rearrangements, like anaplastic lymphoma kinase (

METHODS

Sixty-six patients with advanced stage NSCLC were included in the study. ALK status was determined by immunohistochemistry (IHC) and/or FISH on tissue sections. For the detection of

RESULTS

Of the forty-two patients with an

CONCLUSIONS

The prototype Roche ALK/RET RT-PCR assay was able to detect

Informations de copyright

2021 Annals of Translational Medicine. All rights reserved.

Déclaration de conflit d'intérêts

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/atm-20-7900). SH reports personal fees from Qiagen, personal fees from Boehringer Ingelheim, other from Roche, outside the submitted work. JM is member of the advisory board of Merck, Roche, Astra-Zeneca, MSD, BMS, Pfizer, Hengrui, Daiichi, Boehringer, Pierre Fabre and reports research grants from Roche, Astra-Zeneca, Pierre Fabre. JR, ML and EO are full time employees from Roche Molecular Diagnostics, and have a patent App. No. 62/513,226 pending. DMS reports personal fees from Roche, Pfizer, Takeda, Abbvie, BMS, MSD, Astra Zeneca, Becton Dickinson, Novartis, Boehringer Ingelheim, outside the submitted work. MGD reports personal fees from AstraZeneca, BMS, Boehringer Ingelheim, Roche Diagnostics and grants and personal fees from Takeda, outside the submitted work; PH reports personal fees from Roche, Astra Zeneca, BMS, Novartis, Merck, MSD, Qiagen, Thermo Fisher, Biocartis, outside the submitted work. PH serves an unpaid editorial board member of Annals of Translational Medicine from Jul 2020 to Jun 2022. The authors have no other conflicts of interest to declare.